Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
DDW 2025
2025 AACR Annual Meeting
2025 SSO Annual Meeting
ECO 2025
EAU Congress 2025
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
The ASCO Post Roundtable Series
present case-based, tumor-specific discussions on the latest developments in cancer care. Join key experts in oncology as they discuss the management of challenging clinical scenarios in oncology.
Treatment Approaches to Relapsed Refractory CLL What Comes Next
New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma
Immunotherapy Approaches in Muscle-Invasive Bladder Cancer
PI3K Inhibition Strategies for HR-Positive HER2-Negative Metastatic Breast Cancer
EGFR-Mutant NSCLC Treatment Considerations for Early-Stage Disease
Evolving Paradigms in the Treatment of HR-Positive HER2-Positive Metastatic Breast Cancer
Evolving Treatment Landscape of Indolent Lymphoma
Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease
Personalizing Therapy for Myelofibrosis
Clinical Perspectives on KRAS-Mutant NSCLC
First-Line Immunotherapy for Metastatic NSCLC Special Populations and Unmet Needs
Next-Generation Therapies for Metastatic HR-Positive Breast Cancer
Immunotherapy Strategies for Hepatobiliary Cancers
ALK-Positive Metastatic NSCLC: Where Are We Now
Overcoming Platinum Resistance in Ovarian Cancer
Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL
Treatment Options for Relapsed Refractory Follicular Lymphoma What Comes Next?
Later-Line Considerations in Relapsed Refractory Renal Cell Carcinoma
Addressing Unmet Needs in Myelofibrosis
Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC
Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer
Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC
New Directions in Nonmetastatic Non–Small Cell Lung Cancer
Evolving Skin Cancer Management
Updates in Early-Stage Breast Cancer
Ovarian Function Suppression in Breast Cancer
New Directions in Metastatic Colorectal Cancer
Novel Therapies for Advanced Breast Cancer
Clinical Advances in Diffuse Large B-Cell Lymphoma
Treatment Considerations in Renal Cell Carcinoma
Updates in Myeloproliferative Neoplasms
Clinical Advances in Mantle Cell Lymphoma
Advances in Follicular Lymphoma
Novel Hormonal Therapies for Prostate Cancer
The Evolving Treatment Landscape for Colorectal Cancer
Clinical Considerations in Chronic Graft-vs-Host Disease
Updates in Melanoma
Updates in Hepatobiliary Cancer
Updates in Renal Cell Carcinoma
Updates in Colorectal Cancer
Updates in HER2-Positive Breast Cancer
Updates in Lymphoma
Updates in Prostate Cancer (1)
Updates in Acute Myeloid Leukemia
Updates in Lung Cancer
Updates in Breast Cancer
Updates in Prostate Cancer
Updates in Gynecologic Oncology
Appropriate Management of Challenging Cases in Lung Cancer
Appropriate Management of Challenging Cases in Myeloma and Lymphoma
Advertisement
Advertisement
May
08
Today In Oncology
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL
Survival Trends in Melanoma Brain Metastases Update of Melanoma Graded Prognostic Assessment
Outcomes With HSCT in Pediatric High-Risk AML
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
View More
Advertisement